Volume 122, Issue 7 pp. 1592-1597
Early Detection and Diagnosis

Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer

Geneviève Patry

Geneviève Patry

Centre de recherche en cancérologie de l'Université Laval, CHUQ, L'Hôtel-Dieu de Québec, QC

Search for more papers by this author
Hélène Hovington

Hélène Hovington

Centre de recherche en cancérologie de l'Université Laval, CHUQ, L'Hôtel-Dieu de Québec, QC

Search for more papers by this author
Hélène Larue

Hélène Larue

Centre de recherche en cancérologie de l'Université Laval, CHUQ, L'Hôtel-Dieu de Québec, QC

Search for more papers by this author
François Harel

François Harel

Centre de recherche en cancérologie de l'Université Laval, CHUQ, L'Hôtel-Dieu de Québec, QC

Search for more papers by this author
Yves Fradet

Yves Fradet

Centre de recherche en cancérologie de l'Université Laval, CHUQ, L'Hôtel-Dieu de Québec, QC

Search for more papers by this author
Louis Lacombe

Corresponding Author

Louis Lacombe

Centre de recherche en cancérologie de l'Université Laval, CHUQ, L'Hôtel-Dieu de Québec, QC

Fax: +418-691-5562

Centre de recherche en cancérologie de l'Université Laval, CHUQ-L'Hôtel-Dieu de Québec, 11, côte du Palais, Québec, Canada G1R 2J6Search for more papers by this author
First published: 25 January 2008
Citations: 44

Abstract

Tissue factor (TF), a transmembrane glycoprotein responsible for initiating the extrinsic pathway of blood coagulation plays a key role in cancer growth, metastasis and angiogenesis. Various studies have demonstrated the prognostic potential of TF expression in several cancers. However, its role in bladder cancer is unclear. This study evaluated the prognostic potential of TF expression in muscle-invasive bladder tumors from patients treated with radical cystectomies. Immunohistochemical staining using a monoclonal antibody (mAb) anti-TF was carried out on sections of tissue microarray blocks containing cores of muscle-invasive bladder tumors (4 cores/tumor) from 218 patients. The intensity of the staining was evaluated on a scale from 0 to 3 by two independent observers who were both unaware of the clinicopathological characteristics of the samples. TF was expressed in 77.6% of tumors, independently from baseline characteristics (age, gender, stage and grade) as assessed using the χ2 and Student t tests. During follow-up (median: 2.6 years), 45.4% of the patients died from the progression of their cancer. Kaplan–Meier survival showed that among the 103 patients with node-negative (N0) transitional cell carcinoma (TCC), those with TF-positive tumors had shorter bladder cancer-specific survival (p = 0.0276). Moreover, multivariate Cox regression analysis showed they had a 3.15-fold greater risk of dying from bladder cancer (95% CI: 1.1–9.0; p = 0.032). In conclusion, TF expression was an independent predictor of disease-specific survival in N0 muscle-invasive TCCs treated by radical cystectomy and therefore, might help identify patients at higher risk of disease progression. These patients could potentially benefit from adjuvant chemotherapy. © 2007 Wiley-Liss, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.